• Sisomicin Against Clinical Isolates: 1975 Findings

  2026-10-03

  Stewart and Bodey’s 1975 study evaluated Sisomicin, an aminoglycoside antibiotic, against 565 clinical isolates and compared its in vitro activity with several established agents. The findings showed strong activity against most tested Gram-negative bacilli and Gram-positive cocci, while also revealing cross-resistance with gentamicin- and tobramycin-resistant isolates.

• Metal-Chelating l-Phe Nanostructures and ICB

  2026-10-01

  The reference study shows that metal-ion-chelating l-phenylalanine nanostructures can activate dendritic cells by coupling ion-channel regulation to NLRP3 inflammasome and NF-κB signaling. Short-term starvation enhanced nanostructure uptake and tumor-specific cytotoxic T-cell responses, improving the ability of breast and colorectal tumor models to respond to immune checkpoint blockade.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-10-01

  The 2025 study shows that naturally occurring angiotensin fragments can enhance SARS-CoV-2 spike-protein binding to AXL, with selected shorter peptides also affecting ACE2 and NRP1 interactions. Its peptide-panel design connects renin–angiotensin system biology with viral-receptor biochemistry while highlighting that binding enhancement is not equivalent to demonstrated infection or clinical risk.

• Phosbind Acrylamide for MAPK Phosphorylation Analysis

  2026-09-30

  Phosbind Acrylamide enables antibody-independent analysis of MAPK phosphorylation by resolving mobility shifts in SDS-PAGE. This guide shows how to use the reagent to test causal signaling models, using the soybean GmMKK4–GmMPK6–GmERF113 pathway as a scientifically grounded example.

• Aurora A Overexpression in Retinoblastoma

  2026-09-30

  A 2024 American Journal of Pathology study identifies AURKA overexpression as a clinically relevant feature of retinoblastoma and links high expression with histopathologic factors associated with aggressive disease. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived material, and xenograft models, the work provides a disease-specific rationale for evaluating Aurora A-directed strategies.

• HyperScribe T7 Cy3 RNA Labeling Kit Guide

  2026-09-29

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit supports efficient fluorescent RNA probe synthesis for spatial and blot-based assays. This guide connects its T7 transcription chemistry with the MALAT1–miR-125b–STAT3 sepsis study to show how probe design can strengthen mechanistic interpretation.

• Isradipine (Dynacirc) in Calcium Channel Assays

  2026-09-29

  Isradipine (Dynacirc) offers a practical L-type calcium-channel perturbation for connecting vascular smooth muscle relaxation with neuronal calcium-overload experiments. This guide translates its formulation data and comparative electrophysiology into reproducible workflows for hypertension research, calcium-mediated excitotoxicity, and neurodegenerative disease models.

• 11β-HSD1 Inhibition Rewires Liver Fibrosis

  2026-09-28

  A 2025 mouse study identifies a coordinated anti-fibrotic mechanism in which 11β-HSD1 inhibition lowers intracellular cortisol, suppresses Notch signaling, and increases natural killer cell-mediated clearance of activated hepatic stellate cells. Its combination of biochemical, transcriptomic, and high-dimensional immune profiling provides a useful framework for mechanistic liver fibrosis research, while the thioacetamide model limits direct translation to MASLD and MASH.

• TMRE Mitochondrial Membrane Potential Assay Kit

  2026-09-28

  Learn how to plan and interpret mitochondrial membrane-potential measurements with the TMRE mitochondrial Membrane Potential Assay Kit (SKU K2233). Five laboratory scenarios cover assay controls, sample scale, workflow decisions, and the limits of interpreting TMRE fluorescence as a cell-death readout.

• Cytarabine Beyond Cytotoxicity: Mapping Cell Death

  2026-09-27

  Cytarabine (AraC) is widely used to study DNA damage and apoptosis, but cell-death readouts can conceal distinct mechanisms. This article connects AraC experiments with a viral RIPK3 study to clarify what each assay can—and cannot—establish.

• Nintedanib (BIBF 1120): Mechanism & Research Use

  2026-09-26

  Nintedanib (BIBF 1120) is a multi-target inhibitor of VEGFR, FGFR, and PDGFR signaling used in antiangiogenic and fibrosis research. Its receptor-target profile supports experimental study of angiogenesis inhibition, but ATRX-deficient glioma findings establish class-level sensitivity to receptor tyrosine kinase and PDGFR inhibitors rather than Nintedanib-specific efficacy.

• Gamithromycin PK/PD Targets Against S. suis in Piglets

  2026-09-25

  Wang and colleagues linked gamithromycin exposure to antibacterial response against Streptococcus suis in piglets, identifying AUC24h/MIC as the predictive PK/PD index and defining exposure targets for stasis and bacterial killing. Their analysis also estimated a PK/PD cutoff and a dose for the isolate distribution studied in China, providing a framework for—but not a substitute for—clinical breakpoint and dosing validation.

• v-Agatoxin-IVA Reveals Low-Affinity N-Type Blockade

  2026-09-25

  Sidach and Mintz showed that v-agatoxin-IVA potently blocks P-type calcium channels but can also inhibit a smaller fraction of neuronal N-type current at micromolar concentrations. Their recordings clarify why toxin concentration, voltage dependence, and neuronal preparation matter when using pharmacology to classify calcium-channel currents.

• UBC9–PINK1 SUMOylation in Parkinson’s Disease

  2026-09-24

  A study in cell and mouse models of Parkinson’s disease links the SUMO-conjugating enzyme UBC9 to PINK1 SUMOylation, mitochondrial quality control, and reduced oxidative injury. The findings support a UBC9–PINK1 pathway for further investigation, while leaving questions about mechanism, model relevance, and therapeutic potential open.

• Nebivolol Hydrochloride: β1 Signaling Workflows

  2026-09-24

  Build focused β1-adrenoceptor experiments with a potent, selective antagonist and practical guidance for stock preparation, dose-response design, and assay controls. A drug-sensitized yeast study also sets an important boundary: nebivolol showed no evidence of TOR inhibition in that model, so choose the assay to match the biological question.

8684 records 3/579 page Previous Next 12345 下5页 Last page